Cis-Diamminedichloroplatinum Ii

Bile Duct Cancer

Lisata Therapeutics, Inc.Small moleculePhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

19 Active assets in the Bile Duct Cancer cohort.

Asset / Sponsor	Phase	Rating
Xaliplatin Lisata Therapeutics, Inc.	Phase 2	BB
Celecoxib Seoul National University Hospital	Phase 4	B
Fluorouracilum Lisata Therapeutics, Inc.	Phase 2	B
Pembrolizumab Imugene Limited	Phase 2	B
N-Butyl Cyanoacrylate Minia University	Phase 3	B

View all 29 →

Same molecule, other indications

Cis-Diamminedichloroplatinum Ii is also rated in:

squamous cell lung carcinomaActive

BBB

Indicative · Phase 4

78 / 100

primary peritoneal carcinomaActive

BBB

Indicative · Phase 3

77 / 100

adenocarcinomaActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.